NCT03168737View on ClinicalTrials.gov

18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 22, 2017

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Malignant Breast NeoplasmMalignant Colorectal NeoplasmMalignant Pancreatic NeoplasmMalignant Solid Neoplasm
Interventions
PROCEDURE

Computed Tomography

Undergo PET-CT scan

RADIATION

Fluorine F 18-fluoroazomycin Arabinoside

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET-CT scan

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER